Production of recombinant therapeutic proteins in human cells: Current achievements and future perspectives

Protein and Peptide Letters

Volumn 20, Issue 12, 2013, Pages 1373-1381

  Picanço Castro, Virgínia ^a   Biaggio, Rafael Tagé ^a   Cova, Dimas Tadeu ^a   Swiech, Kamilla ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Expression systems; Human cell lines; Large scale production; Mammalian cell culture; Protein glycosylation; Recombinant proteins

Indexed keywords

ALPHAN3 INTERFERON; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; XIGIRS;

ARTICLE; CAP CELL; CELL LINE; CELL STRAIN HEK293; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HKB11 CELL; HUMAN; IMMUNE RESPONSE; MAMMAL CELL; MOLECULAR CLONING; MOLECULAR DYNAMICS; NONHUMAN; PER C6 CELL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; BIOREACTOR; BIOTECHNOLOGY; GLYCOSYLATION; PROCEDURES; TRENDS;

MAMMALIA;

BIOREACTORS; BIOTECHNOLOGY; CELL LINE; GLYCOSYLATION; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS;

EID: 84887857022     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986652012131112130322     Document Type: Article

References (83)

1. Matasci, M.; Hacker, D.L.; Baldi, L.; Wurm, F.M. Recombinanttherapeutic protein production in cultivated mammalian cells: currentstatus and future prospects. Drug Discovery Today: Technologies, 2008, 5, e37-e42.
2. Rader, R.A. FDA biopharmaceuticals product approvals and trendsin 2012. BioProcess International, 2013, 11, 18-27.
3. Hiller, A. Fast growth foreseen for protein therapeutics. BioMarketTrends, 2009, 29, No. 1 (http://www.genengnews.com/genarticles/fast- growth-foreseen-for-protein-therapeutics/2722/).
4. Zhang, J. In: Manual of Industrial Microbiology and Biotechnology; Richard, H.B.; Davies, J.E.; Demain, A.L., Ed.; ASM Press, 2010; pp. 157-178.
5. Butler, M. Animal cell cultures: recent achievements and perspectivesin the production of biopharmaceuticals. Appl. Microbiol. Biotechnol., 2005, 68, 283-291.
6. Zhu, J. Mammalian cell protein expression for biopharmaceuticalproduction. Biotechnol. Adv., 2012, 30, 1158-1170.
7. Pogue, G.P.; Vojdani, F.; Palmer, K.E.; Hiatt, E.; Hume, S.; Phelps, J. et al. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expressionsystems. Plant Biotechnol. J., 2010, 8, 638-64.
8. Swiech, K.; Picanço-Castro, V.; Covas, D.T. Human cells: NewPlatform for recombinant therapeutic protein production. ProteinExpres. Purif., 2012, 84, 147-153.
9. Houdebine, L.M. Production of pharmaceutical proteins by transgenicanimals. Comp. Immunol. Microbiol. Infect. Dis., 2009, 32, 107-121.
10. Cox, M.M.J. Recombinant protein vaccines produced in insectcells. Vaccine, 2012, 1759-1766.
11. Ikonomou, L.; Schneider, Y.J.; Agathos, S.N. Insect cell culture forindustrial production of recombinant proteins. Appl. Microbiol. Biotechnol., 2003, 62, 1-20.
12. Leavitt, R.; Schlesinger, S.; Kornfeld, S. Impaired intracellularmigration and altered solubility of nonglycosylated glycoproteinsof vesicular Stomatitis virus and Sindbis virus. J. Bio. Chem., 1977, 252, 9018-9023.
13. Wallick, S.C.; Kabat, E.A.; Morrison, S.L. Glycosilation of a VHresidue od a monoclonal antibody against alpha (1-6) dextran increasesits affinity for antigen. J. Exp. Med., 1988, 168, 1099-109.
14. Walsh, M.T.; Watzlawick, H.; Putnam, F.W.; Schmid, K.; Brossmer, R. Effect of the carbohydrate moiety on the secondary structureof beta 2-glycoprotein. I. Implications for the biosynthesis andfolding of glycoproteins. Biochemistry, 1990, 29, 6250-6257.
15. Wyss, D.F.; Wagner, G. The structural role of sugars in glycoproteins. Curr. Opin. Biotechnol., 1990, 7, 409-416.
16. Moreira A.R. The evolution of protein expression and cell culture. Biopharm. Int., 2007, 20, 56-68.
17. Wurm, F.M. Production of recombinant proteins therapeutics incultivated mammalian cells. Nat. Biotechnol., 2004, 22, 1393-1398.
18. Sinclair, A. An industry in transition. Bioprocess Int., 2009, 7, S1.
19. Varki, A. Factors controlling the glycosylation potential of the Golgi apparatus. Trends Cell Biol., 1998, 8, 34-40
20. Rudd, P.M.; Wormald, M.R.; Wing, D.R.; Prusiner, S.B.; Dwek, R.A. Prion glycoprotein: structure, dynamics, and roles for the sugars. Biochemistry, 2001, 40, 3759-66.
21. Gross, V.; Heinrich, P.C.; vom Berg, D.; Steube, K.; Andus, T.; Tran-Thi, T.A.; Decker, K.; Gerok, W. Involvement of various organsin the initial plasma clearance of differently glycosylated ratliver secretory proteins. Eur. J. Biochem., 1988, 173, 653-9.
22. Sathyamoorthy, N.; Decker, J.M.; Sherblom, A.P.; Muchmore, A. Evidence that specific high mannose structures directly regulatemultiple cellular activities. Mol. Cell Biochem., 1991, 102, 139-47.
23. Yan, A.; Lennarz, W.J. Unraveling the mechanism of protein Nglycosylation. J. Biol. Chem., 2005, 280, 3121-4.
24. Peter-Katalinic. Methods in enzymology: O-glycosylation of proteins. Methods Enzymol., 2005, 405, 139-71.
25. Spiro, R.G. Protein glycosylation: nature, distribution, enzymaticformation, and disease implications of glycopeptide bonds. Glycobiology, 2002, 12, 43R-56R.
26. Hua, S.; Nwosu, C.C.; Strum, J.S.; Seipert, R.R.; An, H.J.; Zivkovic, A.M.; German, J.B.; Lebrilla, C.B. Site-specific protein glycosylationanalysis with glycan isomer differentiation. Anal. Bioanal. Chem., 2012, 403, 1291-302.
27. Kaushik, S.; Mohanty, D.; Surolia, A. Role of glycosylation instructure and stability of Erythrinacorallodendronlectin (EcorL): amolecular dynamics study. Protein Sci., 2011, 20, 465-81.
28. Kayser, V.; Chennamsetty, N.; Voynov, V.; Forrer, K.; Helk, B.; Trout, B.L. Glycosylation influences on the aggregation propensityof therapeutic monoclonal antibodies. Biotechnol. J., 2011, 6, 38-44.
29. Li, H.; d'Anjou, M. Pharmacological significance of glycosylationin therapeutic proteins. Curr. Opin. Biotechnol., 2009, 20, 678-84.
30. Öberg, F.; Sjöhamn, J.; Fischer, G.; Moberg, A.; Pedersen, A.; Neutze, R.; Hedfalk, K. Glycosylation increases the thermostabilityof human aquaporin 10 protein. J. Biol. Chem., 2011, 286, 31915-23.
31. Opanasopit, P.; Nishikawa, M.; Yamashita, F.; Takakura, Y.; Hashida, M. Pharmacokinetic analysis of lectin-dependent biodistribution of fucosylated bovine serum albumin: a possible carrier for Kupffer cells. J. Drug Target, 2001, 9, 341-51.
32. Rajagopalan, L.; Organ-Darling, L.E.; Liu, H.; Davidson, A.L.; Raphael, R.M.; Brownell, W.E.; Pereira, F.A. Glycosylation regulatesprestin cellular activity. J. Assoc. Res. Otolaryngol., 2010, 11, 39-51.
33. Straumann, N.; Wind, A.; Leuenberger, T.; Wallimann, T. Effects of N-linked glycosylation on the creatine transporter. Biochem. J., 2006, 393, 459-69.
34. Su, D.; Zhao, H.; Xia, H. Glycosylation-modified erythropoietinwith improved half-life and biological activity. Int. J. Hematol., 2010, 91, 238-44.
35. Gornik, O.; Lauc, G. Glycosylation of serum proteins in inflammatorydiseases. Dis. Markers, 2008, 25, 267-78.
36. Gornik, O.; Wagner, J.; Pucić, M.; Knezević, A.; Redzic, I.; Lauc, G. Changes of serum glycans during sepsis and acute pancreatitis. Glycobiology, 2007, 17, 1321-32.
37. Stanley, P.; Raju, T.S.; Bhaumik, M. CHO cells provide access tonovel N-glycans and developmentally regulated glycosyltransferases. Glycobiology, 1996, 6, 695-9.
38. Ghaderi, D.; Taylor, R.E.; Padler-Karavani, V.; Diaz, S.; Varki, A. Implications of the presence of N-glycolylneuraminic acid in recombinanttherapeutic glycoproteins. Nat. Biotechnol., 2010, 28, 863-7.
39. Galili, U. Immune response, accommodation, and tolerance totransplantation carbohydrate antigens. Transplantation, 2004, 78, 1093-1098.
40. Bardor, M.; Nguyen, D.H; Diaz, S.; Varki, A. Mechanism of uptake and incorporation of the non-human sialic acid Nglycolylneuraminicacid into human cells. J Biol Chem., 2005, 280, 4228-37.
41. Moran, N. Shire's replacement enzymes validate gene activation. Nat. Biotechnol., 2010, 28(11), 1139-1140.
42. Smith, W.B.; Dowell, J.A.; Pratt, R.D. Pharmacokinetics andpharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin. Ther., 2007, 29, 1368-1380.
43. Bekisz, J.; Schmeisser, H.; Hernandez, J.; Goldman, N.D.; Zoon, K.C. Human Interferons Alpha, Beta and Omega. Growth Factors, 2004, 22, 243-251.
44. Tölö, H. Kauppinen, H.L.; Alm, G.; Perers, A.; Lindeberg, E.; Wahlstedt-Fröberg, V.; Parrkkinen, J. Development of a Highly PurifiedMulticomponent Leukocyte IFN-a Product. J. Interferon CytokineRes., 2001, 21, 913-920.
45. Strayer, D.R.; Carter, W.A. Recombinant and Natural Human Interferons:Analysis of the Incidence and Clinical Impact of NeutralizingAntibodies. J. Iinterferon Cytokine Res., 2012, 32, 95-102.
46. Genzel, Y.; Behrendt, I.; Rödig, J.; Rapp, E.; Kueppers, C.; Kochanek, S.; Schiedner, G.; Reichl, U. CAP, a new human suspensioncell line for influenza virus production. Appl. Microbiol. Biotechnol., 2013, 97, 111-122.
47. Fischer, S.; Charara, N.; Gerber, A.; Wolfel, J.; Schiedner, G.; Voedisch, B.; Geisse, S. Transient recombinant protein expressionin a human amniocytecell line: the CAP-T1 cell system. Biotechnol. Bioeng., 2012, 109, 2250-2261.
48. Loignon, M.; Perret, S.; Kelly, J.; Boulais, D.; Cass, B.; Bisson, L.; Afkhamizarreh, F.; Durocher, Y. Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnology, 2008, 8, 1-16.
49. Adam, E.; Sarrazin, S.; Landolfi, C.; Motte, V.; Lortat-Jacob, H.; Lassalle, P.; Delehedde, M. Efficient long-term and high-yieldedproduction of a recombinant proteoglycan in eukaryotic HEK293cells using a membrane-based bioreactor. Biochem. Biophys. Res. Commun., 2008, 369, 297-302.
50. Belin, V.; Rousselle, P. Production of a recombinantly expressedlaminin fragment by HEK293-EBNA cells cultured in suspensionin a dialysis-based bioreactor. Prot. Express. Purif., 2006, 48, 43-48.
51. Sun, X.; Goh, P.E.; Wong, K.T.K.; Mori, T.; Yap, M.G.S. Enhancement of transient gene expression by fed-batch culture of HEK 293 EBNA1 cells in suspension. Biotechnol. Lett., 2006, 28, 843-848.
52. Backliwal, G.; Hildinger, M.; Hasija, V.; Wurm, F. M. High-Density Transfection With HEK-293 Cells Allows Doubling of Transient Titers and Removes Need for A Priori DNA ComplexFormation With PEI. Biotechnol. Bioeng., 2008, 99, 721-727.
53. Wajih, N.; Owen, J.; Wallin, R. Enhanced Functional RecombinantFactor VII Production by HEK 293 Cells Stably Transfected withVKORC1 where the Gamma-Carboxylase Inhibitor Calumenin is Stably Suppressed by shRNA Transfection. Thromb. Res., 2008, 122, 405-410.
54. Dumont, J.A.; Liu, T.; Low, S.C.; Zhang, X.; Kamphaus, G.; Sakorafas, P.; Fraley, C.; Drager, D.; Reidy, T.; McCue, J.; Franck, H.W.G.; Merricks, E.P.; Nichols, T.C.; Bitonti, A.J.; Pierce, G.F.; Jiang, H. Prolonged activity of a recombinant factor VIII-Fc fusionprotein in hemophilia A mice and dogs. Blood, 2012, 119, 1-34.
55. Ross, D.; Brown, T.; Harper, R.; Pamarthi, M.; Nixon, J.; Bromirski, J.; Li, C.M.; Ghali, R.; Xie, H.; Medvedeff, G.; Li, H.; Scuderi, P.; Arora, V.; Hunt, J.; Barnett, T. Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER.C6 cells. J. Biotechnol., 2012, 162, 262-273.
56. Tchoudakova, A.; Hensel, F.; Murillo, A.; Eng, B.; Foley, M.; Smith, L.; Schoenen, F.; Hildebrand, A.; Kelter, A.-R.; Ilag, L. L.; Vollmers, H. P.; Brandlein, S.; McIninch, J.; Chon, J.; Lee, G.; Cacciuttolo, M. High level expression of functional human IgMs inhuman PER.C6® cells. mAbs, 2009, 1, 163-171.
57. Kruif, J.; Kramer, A.; Nijhuis, R.; Zande, V.; Blanken. R.; Clements. C.; Visser, T.; Keehnen, R.; Hartog, M.; Throsby, M.; Logtenberg, T. Generation of Stable Cell Clones Expressing Mixtures of Human Antibodies. Biotechnol. Bioeng., 2010, 106, 741-750.
58. Jones, D.; Kroos, N.; Anema, R.; Montfort, B.; Vooys, A.; Kraats, S.; Helm, E.; Smits, S.; Schouten, J.; Brouwer, K.; Lagerwerf, F.; Berkel, P.; Opstelten, D.; Logtenberg, T.; Bout, A. High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol. Prog., 2003, 19, 163-168.
59. Schiedner, G.; Hertel, S.; Bialek, C.; Kewes, H.; Waschütza G.; Volpers, C. Efficient and reproducible generation of highexpressing, stable human cell lines without need for antibiotic selection. BMC Biotechnology, 2008, 8, 1-11.
60. Mei, B.; Pan, C.; Jiang, H.; Tjandra, H.; Strauss, J.; Chen, Y.; Liu, T.; Zhang, X.; Severs, J.; Newgren, J.; Chen, J.; Gu, J.-M.; Subramanyam, B.; Fournel, M. A.; Pierce, G. F.; Murphy, J. E. Rationaldesign of a fully active, long-acting PEGylated factor VIII for hemophiliaA treatment. Blood, 2010, 116, 270-279.
61. Mei, B.; Chen, Y.; Chen, J.; Pan, C.Q.; Murphy, J.E. Expression of Human Coagulation Factor VIII in a Human Hybrid Cell Line, HKB11. Mol. Biotechnol., 2006, 34, 165-178.
62. Cho, M.S.; Yee, H.; Chan, S. Establishment of a Human SomaticHybrid Cell Line for Recombinant Protein Production. J. Biomed. Sci., 2002, 9, 631-638.
63. Tang, L.; Leong, L.; Sim, D.; Ho, E.; Gu, J.-M.; Schneider, D.; Feldman, R. I.; Monteclaro, F.; JIANG, H.; MURPHY, J. E. vonWillebr and factor contributes to longer half-life of PEGylated factorVIII in vivo. Haemophilia, 2013, 1-7.
64. Yallop, C.; Crowley, J.; Cote, J.; Hegmans-Brouwer, K.; Lagerwerf, F.; Gagne, R.; Martin, J.C.; Oosterhuis, N.; Opstelten, D.J.; Bout, A. In: Modern Biopharmaceuticals: Design, Development and Optimization; Knablein, J., Ed.; Wiley-VCH:Weinheim, 2005, pp. 779-807.
65. Havenga, M.J.; Holterman, L.; Melis, I.; Smits, S.; Kaspers, J.; Heemskerk, E.; van der Vlugt, R.; Koldijk, M.; Schouten, G.J.; Hateboer, G.; Brouwer, K.; Vogels, R.; Goudsmit, J. Serum-freetransient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity. Biotechnol. Bioeng., 2008, 100, 273-283.
66. Coco-Martin, J.M.; Harmsen, M.M. A review of therapeutic proteinexpression by mammalian cells. BioProcess Int., 2008, 6, 28-33.
67. Crowley, J. et al. Process Optimization of the Human Cell LinePER.C6 for the Production of Biopharmacueticals, Procedding of the Cell Culture Engineering IX, Cancun, Mexico, March 7-12, 2004.
68. Nichols, W.W.; Lardenoije, R.; Ledwith, B.J.; Brouwer, K.; Manam, S.; Vogels, R.; Kaslow, D.; Zuidgeest, D.; Bett, A.J.; Chen, L.; vander Kaaden, M.; Galloway, S.M.; Hill, R.B.; Machotka, S.V.; Anderson, C.A.; Lewis, J.; Martinez, D.; Lebron, J.; Russo, C.; Valerio, D.; Bout, A. In: Adenoviral Vectors for Gene Therapy, Curiel, D.T.; Douglas, J.T., Eds.; Academic Press: New York, 2002, 129166.
69. Durocher, Y.; Butler, M. Expression systems for therapeutic glycoproteinproduction. Curr. Opin. Biotech., 2009, 20, 700-707.
70. Essers, R.; Kewes, H.; Schiedner, G. Improving volumetric productivityof a stable human CAP cell line by bioprocess optimization. BMC Proceedings, 2011, 5, P66.
71. Cho, M.S. Human hybrid host cell for mammalian gene expression. U.S. Patent 6136599, October 24, 2000.
72. Apeler, H. In: Modern Biopharmaceuticals: Design, Development and Optimization; Knablein, J., Ed.; Wiley-VCH:Weinheim, 2005, pp. 1021-1031.
73. Graham, F.L.; Smiley, J.; Russell, W.C.; Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirustype 5. J. Gen. Virol., 1977, 36, 59-67.
74. Suttie, J.W. Report of workshop on expression of vitamin kdependentproteinsin bacterial and mammalian cells. Thromb. Res., 1986, 44, 129-134.
75. Aricescu, A.R.; Owens, R.J. Expression of recombinant glycoproteinsin mammalian cells: towards an integrative approach to structuralbiology. Curr. Opin. Struct. Biol., 2013, 23, 345-356.
76. Thomas, P.; Smart, T.G. HEK293 cell line: A vehicle for the expressionof recombinant proteins. J. Pharm. Toxicol. Methods, 2005, 51, 187-200.
77. Chapple, S.D.; Crofts, A.M.; Shadbolt, S.P.; McCafferty, J.; Dyson, M.R. Multiplexedexpression and screening for recombinant proteinproduction in mammaliancells. BMC Biotechnol., 2006, 6, 49.
78. Schlaeger, E.J.; Christensen, K. Transient gene expression inmammalian cellsgrown in serum-free suspension culture. Cytotechnol., 1999, 30, 71-83.
79. Wurm, F.; Bernard, A. Large-scale transient expression in mammaliancells forrecombinant protein production. Curr. Opin. Biotechnol., 1999, 10, 156-159.
80. Baldi, L.; Muller, N.; Picasso, S.; Jacquet, R.; Girard, P.; Thanh, H.P.; Derow, E.; Wurm, F.M. Transient gene expression in suspensionHEK-293 cells: application tolarge-scale protein production. Biotechnol. Prog., 2005, 21, 148-153.
81. Durocher, Y.; Perret, S.; Kamen, A. High-level and high throughputrecombinant protein production by transient transfection of suspension-growing human293-EBNA1 cells. Nucl. Acids Res., 2002, 30, E9.
82. Geisse, S.; Henke, M. Large-scale transient transfection of mammaliancells: anewly emerging attractive option for recombinantprotein production, J. Struct. Funct. Genomics, 2005, 6, 165-170.
83. Pham, P.L.; Kamen, A.; Durocher, Y. Large-scale transfection ofmammalian cells for the fast production of recombinant protein. Mol. Biotechnol., 2006, 34, 225-237.